A first-in-human phase 1 study of a hepcidin monoclonal antibody, LY2787106, in cancer-associated anemia
Saroj Vadhan‐Raj(The University of Texas MD Anderson Cancer Center), Eric Roeland(Harvard University), Jonathan W. Goldman(University of California, Los Angeles), Rafat Abonour, Sophie Callies, Jay Tuttle(Eli Lilly (United States)), Joanne Cox(Eli Lilly (United Kingdom)), Xuejing Wang(Wannan Medical College), David A. Smith(Compass Oncology), Yiu-Keung Lau(Eli Lilly (United States)), Christopher A. Slapak(Eli Lilly (United States)), Ramón V. Tiu(Eli Lilly (United States)), Robert Ilaria(Eli Lilly (United States))
Cited by 88
Related Papers
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k
Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma
|Journal of Clinical Oncology|2011|1.3k
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers
|New England Journal of Medicine|2020|766